Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05378555 · ClinicalTrials.gov registry record · Phase 3
Oral Ketamine for Treatment of Vaso-Occlusive Pain
A Phase 3 study of Vaso-occlusive Crisis, sponsored by Boston Children's Hospital.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT05378555 is a Phase 3 study of Vaso-occlusive Crisis that is actively recruiting participants, run by Boston Children's Hospital. The registered enrollment target is 10 participants, below the 89-participant average among 4 other Vaso-occlusive Crisis trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05378555, a Phase 3 study of Vaso-occlusive Crisis, is actively recruiting participants, sponsored by Boston Children's Hospital.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to learn more about the feasibility of oral ketamine for the treatment of painful sickle-cell crises in children and adolescents as a supplement to intravenous (IV) opioids. There is a need for improved non-opioid analgesia for patients experiencing sickle-cell crises in the hospital and prehospital setting, as children and adolescents with sickle cell disease who experience sickle-cell crises often have severe pain that is not well controlled by high dose opioids, leading to poor pain management and opioid-related side effects. The study will begin when patients are admitted to the Emergency Department of Boston Children's Hospital for treatment of a sickle-cell crisis. Oral ketamine will be administered every 8 hours for the next 48 hours. Patients will have continuous cardiorespiratory monitoring for the duration of the study, as per routine care, as well as monitoring by the hospital's Acute Pain Service at least twice daily for pain management and side effects of pain treatment. At the end of the 48-hour study duration, patients will discuss with the Pain Service and Hematology Service whether to continue oral ketamine, change to intravenous ketamine, or discontinue ketamine based on clinical indications such as level of pain and sedation while on opioids.
Conditions Studied
Interventions
- DRUG Ketamine Hydrochloride
Study Locations (1)
Massachusetts
- Boston Children's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2023-05-01 |
| Est. Completion | 2026-06-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05378555
The ClinicalTrials.gov registry entry for NCT05378555 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 89-participant average among 4 other Vaso-occlusive Crisis trials with a reported enrollment target (89% lower). The listed sponsor is Boston Children's Hospital, which has 462 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Vaso-occlusive Crisis appearing as the primary indexed condition, and to 1 intervention - of which Ketamine Hydrochloride is the first listed.
NCT05378555 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05378555 about?
NCT05378555 is a clinical study titled "Oral Ketamine for Treatment of Vaso-Occlusive Pain". The purpose of this study is to learn more about the feasibility of oral ketamine for the treatment of painful sickle-cell crises in children and adolescents as a supplement to intravenous (IV) opioids. There is a need for improved non-opioid analgesia for patients experiencing sickle-cell crises in...
What is the current status of trial NCT05378555?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 10 participants. The study started on 2023-05-01. Estimated completion is 2026-06-01.
What conditions does trial NCT05378555 study?
This clinical trial studies the following conditions: Vaso-occlusive Crisis.
What interventions are being tested in trial NCT05378555?
The interventions under investigation include: Ketamine Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT05378555?
This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05378555 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Vaso-occlusive Crisis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises
COMPLETED · Phase 3
-
Effect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease
RECRUITING · NA
-
Nitrous Oxide Analgesia Vaso-occlusive Crisis
COMPLETED · Phase 2
-
Treatment of Sickle Cell Patients Hospitalized in Pain Crisis With Prophylactic Dose Low-molecular-weight Heparin (LMWH) Versus Placebo
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.